Early Detection
Identify Alzheimer’s risk years before symptoms appear, allowing for timely intervention and better management options.
Non-Invasive
Our retina imaging technology offers a quick, non-invasive alternative to traditional brain scans, ensuring a comfortable patient experience.
Cost-Effective
Reduce diagnostic expenses with our accessible screening solution, designed to be affordable for healthcare providers and patients alike.
High Precision
Gain reliable insights with hyperspectral imaging, accurately measuring key biomarkers associated with Alzheimer’s progression.
Why Retinal Hyperspectral Imaging Matters
Alzheimer’s Disease affects millions worldwide, with cases expected to rise sharply as populations age. Detecting the disease early can make a critical difference, but traditional methods are costly, invasive, and often unavailable for large-scale screening.
RetinalImaging’s retinal hyperspectral imaging technology changes this landscape by offering a non-invasive, affordable way to detect Alzheimer’s risk years before symptoms emerge. By analyzing amyloid deposits in the retina—a window into brain health—our technology provides accessible and reliable insights, making early intervention possible and significantly reducing the burden on healthcare systems. Retinal Imaging not only supports patients and caregivers but also transforms how we approach preventive care for neurodegenerative diseases.
Contact us to learn moreAbout Us
Revolutionizing Alzheimer’s Detection with Advanced Retinal Imaging Technology
RetinalImaging is a Canadian health technology company focused on pioneering retinal hyperspectral imaging to advance early Alzheimer’s detection. Our mission is to provide an accessible, non-invasive, and cost-effective solution that empowers healthcare providers and patients alike. We are committed to pushing the boundaries of preventive care, transforming how neurodegenerative diseases are screened, and ultimately improving patient outcomes worldwide.
- Our advanced imaging technology detects Alzheimer’s biomarkers through the retina, offering a unique, non-invasive alternative to costly brain scans.
- Designed with comfort in mind, our technology makes early Alzheimer’s screening accessible and stress-free for patients.
- By significantly reducing screening costs, we enable healthcare providers to expand early detection efforts, easing the strain on medical resources.
- With hyperspectral imaging, we deliver precise measurements of retinal amyloid levels, correlated with brain health, enhancing diagnostic accuracy.
Technology
Revolutionary Technology Behind RetinalImaging
RetinalImaging’s groundbreaking hyperspectral imaging technology allows for early detection of Alzheimer’s Disease through a simple retinal scan. By analyzing amyloid deposits in the retina—a key indicator of brain health—our technology provides a non-invasive, accessible, and accurate diagnostic tool. Unlike traditional, invasive brain scans, retinal imaging opens the door for widespread, preventive Alzheimer’s screening.
Early Intervention
By detecting Alzheimer’s risk in its earliest stages, our technology enables timely intervention, potentially slowing disease progression and improving patient quality of life.
Greater Accessibility
Retinal imaging is an affordable alternative to brain PET scans, allowing more patients to benefit from early detection without financial strain.
Reduced Healthcare Burden
Non-invasive and quick, retinal imaging reduces the need for extensive resources, freeing up healthcare systems to better serve the growing population at risk for Alzheimer’s
Improved Patient Outcomes
With high precision in detecting Alzheimer’s biomarkers, retinal imaging supports accurate diagnosis, leading to better-informed care plans and more positive patient trajectories.

Services
RetinalImaging provides variaty of services for customers from individuals to organizations.
Alzheimer’s Risk Screening
Using advanced retinal imaging, we offer non-invasive Alzheimer’s risk screenings that are both accurate and accessible. This service enables early detection to aid in preventive care.
Diagnostic Support
Our imaging results support healthcare professionals with precise data on Alzheimer’s biomarkers, enhancing their diagnostic capabilities. This service ensures clinicians have reliable insights to guide patient care.
Mobile Screening Units
We offer mobile units equipped with retinal imaging technology, bringing Alzheimer’s screenings directly to community clinics and elder care facilities. This expands access to high-quality, early diagnostic options.
Corporate Wellness Programs
RetinalImaging partners with companies to provide Alzheimer’s screenings as part of employee wellness initiatives. This service promotes preventive health and well-being within the workplace.
Training for Medical Professionals
We provide comprehensive training programs for healthcare providers on the use of retinal imaging technology. This ensures accurate interpretation and optimized use of our screening technology.
Research Collaboration
RetinalImaging collaborates with research institutions to advance studies on Alzheimer’s detection and retinal imaging. Together, we’re working to refine and expand applications of our technology in neurodegenerative care.
Team Members
ReginalImaging cannot have success without talent members.
Limin Chen
FounderAs the Founder of RetinalImaging, Limin Chen brings a visionary approach to early Alzheimer’s detection through innovative health technology. With a strong background in medical imaging and a commitment to advancing preventive care, Limin has led the development of cutting-edge retinal hyperspectral imaging to make Alzheimer’s screenings more accessible and affordable. Under Limin’s guidance, RetinalImaging continues to pioneer solutions that transform neurodegenerative care worldwide.
Rongbo Zhao
Purchasing DirectorWith a keen eye for quality and an unwavering commitment to cost efficiency, Rongbo brings exceptional expertise to his role as Purchasing Director. He has a proven track record of building strong, sustainable supplier relationships and ensuring that procurement aligns seamlessly with the company's strategic goals. His approach to sourcing and vendor management not only optimizes resources but also drives innovation and quality across the board.
Xin Ran
Marketing DirectorAs Marketing Director, Xin spearheads all brand, communication, and digital initiatives, shaping the company's public presence and engagement strategy. With a strategic mindset and a creative edge, she has a remarkable ability to connect with target audiences and craft compelling marketing campaigns. Her leadership has been pivotal in driving growth, enhancing brand visibility, and positioning the company at the forefront of industry innovation.
Jingjing Ma
Project ManagerJingjing is a dynamic Project Manager known for her methodical approach to project planning and her skill in coordinating diverse teams to meet project goals. She excels in ensuring projects are delivered on time and within budget, all while maintaining a high standard of quality. Her leadership in managing complex projects has been instrumental in helping the company meet and exceed client expectations consistently.
Xin Li
Risk Control ManagerXin serves as Risk Control Manager, where he is dedicated to safeguarding the company’s operations through comprehensive risk assessment and mitigation strategies. With deep expertise in identifying potential risks and implementing effective control measures, he strengthens the company’s resilience and ensures sustainable growth. His meticulous approach to risk management is a cornerstone of the company's commitment to secure and responsible business practices.
Frequently Asked Questions
We are here to help!
What is retinal hyperspectral imaging?
Retinal hyperspectral imaging is an advanced technology that captures detailed images of the retina to identify biomarkers associated with Alzheimer’s Disease. It provides a non-invasive, cost-effective way to assess Alzheimer’s risk.
How does retinal imaging detect Alzheimer’s Disease?
Our technology analyzes amyloid deposits in the retina, which are linked to brain health and Alzheimer’s. By identifying these deposits early, we can provide insights years before symptoms typically appear.
Is retinal imaging safe?
Yes, retinal imaging is completely safe and non-invasive. It does not use any harmful radiation and is comfortable for patients of all ages.
How long does a screening take?
A retinal imaging screening takes only a few minutes. After a brief period, results can be reviewed, making it a quick and efficient diagnostic tool.
Who should consider getting a retinal imaging screening?
Anyone concerned about Alzheimer’s risk, especially those with a family history of the disease or individuals over the age of 50, may benefit from early screening through retinal imaging.
Can this technology replace traditional Alzheimer’s diagnostic methods?
While retinal imaging is an excellent tool for early screening, it is designed to complement traditional diagnostic methods, providing preliminary insights that can guide further assessment if needed.
Contact
We would love to hear from you.
Address
136 Market Ave #800, Winnipeg, MB R3B 0P4
Call Us
+1
Email Us
info@RetinalImaging.ca